Abstract: A physiologically active composition is claimed which comprises effective amounts of at least one compound from the group 4-O-methyldavidigenin, 4?-O-methyldavidigenin, davidigenin, elemicin, isoelemicin, herniarin, demethoxycapillarisin, in particular 6-demethoxycapillarisin and/or 6-demethoxy-3?-methoxy-capillarisin, hispiludin and 9-hydroxy-10E, 12Z, 15Z-octadecatrienoic acid, and also glycosides thereof, in particular glucosides and/or rhamnoglucosides of 4-O-methyldavidigenin and/or 4?-O-methyldavidigenin, salts and derivatives.

Abstract: The invention relates to polysaccharide derivatives consisting of a biopolysaccharide skeleton and organic groups with a molecular weight <5 000 that are connected to said skeleton via ether bridges. The organic groups have the general formula (Ia) or (Ib). Preferably, ?- or ?-(1,4)- and/or ? or ?-(1,3)-glucan units are used as the biopolysaccharide component, such as e.g. xy-loglucans, glucomannans such as guar gum or locust bean gum, xanthan gum, carrageenans, alginates and pectins. The invention also relates to a method for producing said polysaccharide derivatives, according to which the biopolysaccharide component is reacted with an N-alkyl maleamic acid or a salt thereof in the presence of a base catalyst, whereby the maleamide component can also be cyclised prior to or following the reaction with the biopolysaccharide component.

Abstract: This physiologically active composition contains, as physiologically active constituents, the components a) phosphatidylserine and/or lysophosphatidylserine (in each case “PS”) and b) at least one (lyso)phospholipid different from component a) and c) a serine source different from component a), for example L-serine and/or O-phospho-L-serine. In this composition, the components a) and also b) and c) must each be present in a molar ratio a:b (where b<c) and a:c (where c<b) such that the components b) and c) can preferably form PS in vivo and in this manner ideally replace 10 to 99% by weight of the PS portion in the total formulation. The component a) should here make up 0.1 to 20% by weight of the total formulation and the components b) and c) should be present in portions between 15 and 65% by weight and in portions between 0.1 and 5.0% by weight, respectively.

Abstract: A cofactor having an aromatic or benzylic amino group is converted into an isothiocyanate by reaction with a compound such as thiophosgene and the isothiocyanate of the cofactor is attached to a polymer which is preferably water-soluble. When the polymer has amino groups, a thiourea bridge is formed between the polymer and cofactor and a polymer having hydroxyl groups results in a thiocarbamate bridge. The polymer may be a copolymer of vinylamine or vinylmethylamine and vinylmethylacetamide, partially alkylamine-substituted .alpha., .beta.-poly-(2-hydroxyethyl)-D,L-aspartamide, polyethyleneimine or carbohydrate. The cofactor bound to a polymer and an enzyme are contained in microcapsules or in a membrane to form an enzyme reactor.

Abstract: Streptazoline is reacted with naphthoquinones in a Diels-Alder reaction, and the adduct is then oxidized. The resulting compounds have cytotoxic activity, in particular against leukemia cells, and have an antimicrobial action and act against protozoa.

Abstract: In the process for the preparation of 4-benzyl aspartate starting from dibenzyl aspartate and/or its salts only one benzyl group is selectively removed by catalytic hydrogenation. By setting up appropriate reaction conditions elimination takes place mainly of the benzyl group on the C.sub.1 atom of the compound. The desired product can be isolated from the reaction mixture by precipitation.